HDAC Inhibitors – A Pipeline Analysis Report 2018 Size, Share, Industry, Forecast and outlook (2024-2031) 2026
The HDAC Inhibitors – A Pipeline Analysis Report 2018 Size, Share, Industry, Forecast and outlook (2024-2031) was valued at in and is anticipated to reach by , at a CAGR of xx% from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the HDAC Inhibitors – A Pipeline Analysis Report 2018 Size, Share, Industry, Forecast and outlook (2024-2031).
This report delivers a comprehensive overview of the HDAC Inhibitors – A Pipeline Analysis Report 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding HDAC Inhibitors – A Pipeline Analysis Report 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The HDAC Inhibitors – A Pipeline Analysis Report 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
HDAC Inhibitors – A Pipeline Analysis Report 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Scope:
Major Highlights
This report delivers a comprehensive overview of the HDAC Inhibitors – A Pipeline Analysis Report 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding HDAC Inhibitors – A Pipeline Analysis Report 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The HDAC Inhibitors – A Pipeline Analysis Report 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the HDAC Inhibitors – A Pipeline Analysis Report 2018 Size, Share, Industry, Forecast and outlook (2024-2031).
This report delivers a comprehensive overview of the HDAC Inhibitors – A Pipeline Analysis Report 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding HDAC Inhibitors – A Pipeline Analysis Report 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The HDAC Inhibitors – A Pipeline Analysis Report 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
HDAC Inhibitors – A Pipeline Analysis Report 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Scope:
Major Highlights
This report delivers a comprehensive overview of the HDAC Inhibitors – A Pipeline Analysis Report 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding HDAC Inhibitors – A Pipeline Analysis Report 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The HDAC Inhibitors – A Pipeline Analysis Report 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Increase Your Customer Base by 3X using our Partner Identification tool
- Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
- Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
- Prioritize partners by strategic fit rather than general capability.
- Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
- Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
- White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
- Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
- Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
- Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
HDAC INHIBITORS PIPELINE ANALYSIS
• Histone Deacetylase (HDAC), the superfamily group of enzymes responsible for removal of acetyl groups present on acetyl lysine amino acid attached to histone.
• They are responsible for gene expression and regulation, which is responsible for cellular functioning. It also helps in the wrapping of histone over the Deoxyribonucleic acid (DNA). It has an extended history of use in psychiatry and neurology as anti-epileptics and mood stabilizers.
• More recently they are being explored as possible treatments for cancer, parasitic and inflammatory diseases. Thus, the development of HDAC inhibitors, targeted drug molecules inhibit the activity of HDACs, gains a lot of interest from academic researchers and biopharmaceutical firms.
• A problem arising with the already available HDAC inhibitors is that they target multiple deacetylases and have limited specificity. Designing isoform-selective inhibitors have proven troublesome due to similarities in the structure and chemistry of active sites of HDAC.
• Globally, an increase in the number of cancer patients across the globe and the need to improve the effectiveness of new therapies are the prime growth drivers of HDAC inhibitors market. However, many challenges stick around due to the complexity involved in the lysine posttranslational modifications, non-epigenetic cellular signaling cascades, and epigenetic transcription regulation.
• With the availability of a limited number of marketed HDAC inhibitors, pharmaceutical companies are now heavily investing in research and development activities and preclinical activities of HDAC inhibitors for different applications.
• There are some of the commercialized HDAC inhibitors, most of them are primarily targeting hematological malignancies. Approval of the first HDAC inhibitor, Zolinza (vorinostat) developed by Merck & Co., Inc., for CTCL treatment gave the market an initial impulse.
• The instigation was carried on by the other molecules Istodax developed by Gloucester pharmaceuticals, Beleodaq by Spectrum Pharmaceuticals, Epidaza by Chipscreen Bioscience and Farydak by Novartis. Nearly 90 HDAC inhibitors are at present in various stages of development both clinically and preclinically, of which the clinical molecules account for over 30% of the pipeline molecules capture over 60% in the preclinical / discovery stage.
• Few of the key pipeline HDAC inhibitors include entinostat by Syndax Pharmaceuticals, pracinostat (SB939) by MEI Pharma, abexinostat by Celera Genomics Group, CHR-5154, CKD-581, RG2833, MPT0E028, and CS3158. These are analyzed based on the route of administration (ROA) and type of molecule.
• Histone Deacetylase (HDAC), the superfamily group of enzymes responsible for removal of acetyl groups present on acetyl lysine amino acid attached to histone.
• They are responsible for gene expression and regulation, which is responsible for cellular functioning. It also helps in the wrapping of histone over the Deoxyribonucleic acid (DNA). It has an extended history of use in psychiatry and neurology as anti-epileptics and mood stabilizers.
• More recently they are being explored as possible treatments for cancer, parasitic and inflammatory diseases. Thus, the development of HDAC inhibitors, targeted drug molecules inhibit the activity of HDACs, gains a lot of interest from academic researchers and biopharmaceutical firms.
• A problem arising with the already available HDAC inhibitors is that they target multiple deacetylases and have limited specificity. Designing isoform-selective inhibitors have proven troublesome due to similarities in the structure and chemistry of active sites of HDAC.
• Globally, an increase in the number of cancer patients across the globe and the need to improve the effectiveness of new therapies are the prime growth drivers of HDAC inhibitors market. However, many challenges stick around due to the complexity involved in the lysine posttranslational modifications, non-epigenetic cellular signaling cascades, and epigenetic transcription regulation.
• With the availability of a limited number of marketed HDAC inhibitors, pharmaceutical companies are now heavily investing in research and development activities and preclinical activities of HDAC inhibitors for different applications.
• There are some of the commercialized HDAC inhibitors, most of them are primarily targeting hematological malignancies. Approval of the first HDAC inhibitor, Zolinza (vorinostat) developed by Merck & Co., Inc., for CTCL treatment gave the market an initial impulse.
• The instigation was carried on by the other molecules Istodax developed by Gloucester pharmaceuticals, Beleodaq by Spectrum Pharmaceuticals, Epidaza by Chipscreen Bioscience and Farydak by Novartis. Nearly 90 HDAC inhibitors are at present in various stages of development both clinically and preclinically, of which the clinical molecules account for over 30% of the pipeline molecules capture over 60% in the preclinical / discovery stage.
• Few of the key pipeline HDAC inhibitors include entinostat by Syndax Pharmaceuticals, pracinostat (SB939) by MEI Pharma, abexinostat by Celera Genomics Group, CHR-5154, CKD-581, RG2833, MPT0E028, and CS3158. These are analyzed based on the route of administration (ROA) and type of molecule.
